AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26109819 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant streptokinase (rSK) suppositories (both schedules)
Number of subjects: 421
Study 26109819 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone acetate suppositories
Number of subjects: 421
Study 26109819 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant streptokinase (rSK) suppositories
Number of subjects: 421
Study 22987606 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Patient Data (IPD)
Number of subjects: 0
Study 22987606 — intervention group
Group type: COMPARATOR
Intervention: Aggregate Data (AD)
Number of subjects: 0
Study 22987606 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IPD and AD
Number of subjects: 0
Study 21851342 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion at 3 cm
Number of subjects: 102
Study 21851342 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion at 5 cm
Number of subjects: 102
Study 21851342 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion at 7 cm
Number of subjects: 102
Study 19463125 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0
Study 19463125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17535995 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 0.33 mg/kg body weight per week for a mean of 6.7 years
Number of subjects: 31
Study 17535995 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 31
Study 17535995 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 31
Study 15470332 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW extract with high HYF content (900 mg/d)
Number of subjects: 10
Study 15470332 — intervention group
Group type: COMPARATOR
Intervention: SJW extract with low HYF content (900 mg/d)
Number of subjects: 10
Study 11468503 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthwise Communities Project (free self-care resources)
Number of subjects: 1812
Study 9503767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral interventions
Number of subjects: 10
Study 9503767 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 7508396 — intervention group
Group type: EXPERIMENTAL
Intervention: 960 mg cotrimoxazole and 10 mg oxazepam (group B)
Number of subjects: 83
Study 7508396 — intervention group
Group type: COMPARATOR
Intervention: 960 mg cotrimoxazole (group A)
Number of subjects: 83
Study 2730051 — intervention group
Group type: EXPERIMENTAL
Intervention: Juzentaiho-to (JTT) combined with chemoendocrine therapy
Number of subjects: 130
Study 2730051 — intervention group
Group type: COMPARATOR
Intervention: Chemoendocrine therapy only
Number of subjects: 130
Study 807995 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexical diet (semi‐hydrolyzed diet: 10 g % casein hydrolsate; 14 g % triglycerides, 20% of which medium chain; 66% disaccharides)
Number of subjects: 18
Study 807995 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (control group)
Number of subjects: 18
Study 31161580 — intervention group
Group type: EXPERIMENTAL
Intervention: +O-desmethyltramadol (200 mg extended-release tablets)
Number of subjects: 29
Study 31161580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29250545 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (preoperative and postoperative administration)
Number of subjects: 130
Study 25450879 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 25 mg/m² and etoposide 100 mg/m² intravenously on days 1 to 3 (control arm)
Number of subjects: 206
Study 25450879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 25 mg/m² and etoposide 100 mg/m² combined with bevacizumab 7.5 mg/kg intravenously on day 1 (experimental arm)
Number of subjects: 206
Study 23539943 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program using the PRECEDE‐PROCEED Model
Number of subjects: 100
Study 23539943 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 100
Study 23539943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education program)
Number of subjects: 100
Study 21735279 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile neurofeedback training for 10 days based on sway analysis
Number of subjects: 36
Study 21735279 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 36
Study 19761721 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epoietin-beta (0.3 ml = 4000 IU)
Number of subjects: 42
Study 19761721 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous darbepoietin-alpha (0.5 ml = 20 microg)
Number of subjects: 42
Study 19761721 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (0.3 ml)
Number of subjects: 42
Study 19761721 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (0.5 ml)
Number of subjects: 42
Study 19761721 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epoietin-beta
Number of subjects: 42
Study 19761721 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous darbepoietin-alpha
Number of subjects: 42
Study 16766740 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia via endovascular approach
Number of subjects: 10
Study 15293466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of traditional Chinese medicine and western medicine with massage and functional exercise (trial group)
Number of subjects: 83
Study 15293466 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine and western medicine without massage and functional exercise (control group)
Number of subjects: 83
Study 11062863 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of zolpidem (ZLP)
Number of subjects: 0
Study 11062863 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of zopiclone (ZPC)
Number of subjects: 0
Study 11062863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11062863 — intervention group
Group type: EXPERIMENTAL
Intervention: ZLP
Number of subjects: 0
Study 11062863 — intervention group
Group type: EXPERIMENTAL
Intervention: ZPC
Number of subjects: 0
Study 9323395 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions in 6 intervention subsites
Number of subjects: 11
Study 9323395 — intervention group
Group type: COMPARATOR
Intervention: Control subsites (5)
Number of subjects: 11
Study 8405631 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol transdermally 0.05 mg/day on days 1‐24 and medroxyprogesterone acetate 10 mg/day orally on days 15‐24 (sequential schedule)
Number of subjects: 60
Study 8405631 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol transdermally 0.05 mg/day and medroxyprogesterone acetate 2.5 mg/day orally on days 1‐24 (continuous schedule)
Number of subjects: 60
Study 8405631 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol 0.05 mg/day continuously (in patients who had total abdominal hysterectomy+bilateral salphingooopherectomy)
Number of subjects: 60
Study 2945332 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (1.0 mg administered intracoronarily, distal from the stenosis)
Number of subjects: 20
Study 2945332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30621471 — intervention group
Group type: EXPERIMENTAL
Intervention: Guluronic acid (G2013) 500 mg orally twice a day for 12 weeks
Number of subjects: 0
Study 30621471 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 30621471 — intervention group
Group type: EXPERIMENTAL
Intervention: Guluronic acid (G2013)
Number of subjects: 0
Study 28315478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home-based integrated palliative care teams
Number of subjects: 31
Study 28315478 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 31
Study 25068947 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 10 mg/kg intravenously 5 min before skin incision
Number of subjects: 124
Study 25068947 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 124
Study 23297844 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D3 supplementation (600 mg elemental calcium and 125 IU vitamin D3) with energy-restricted diet (‐500 kcal/d)
Number of subjects: 53
Study 21296263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoints mesotherapy (ACP mesotherapy, n=33)
Number of subjects: 62
Study 21296263 — intervention group
Group type: COMPARATOR
Intervention: Trigger point mesotherapy (TRP mesotherapy, n=29)
Number of subjects: 62
Study 19131454 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidised nicotine replacement therapy (NRT) plus multisession counselling from the quitline
Number of subjects: 1377
Study 19131454 — intervention group
Group type: COMPARATOR
Intervention: Usual quitline service only (comparison group)
Number of subjects: 1377
Study 16977507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate
Number of subjects: 203
Study 16977507 — intervention group
Group type: COMPARATOR
Intervention: Magaldrate
Number of subjects: 203
Study 14749454 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g orally per day)
Number of subjects: 1649
Study 14749454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1649
Study 11705818 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 20 mg
Number of subjects: 142
Study 11705818 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 40 mg
Number of subjects: 142
Study 11705818 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 10 mg
Number of subjects: 142
Study 11705818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 9237061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium supplementation with 2 g calcium per day
Number of subjects: 655
Study 9237061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dietary supplementation with 3.8 g of ispaghula husk
Number of subjects: 655
Study 9237061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study 7970514 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial 10-0 nylon suture combined with fibrin glue for wound closure
Number of subjects: 153
Study 7970514 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue only for wound closure (control group)
Number of subjects: 153
Study 2884081 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 4.4 mg
Number of subjects: 12
Study 2884081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 2.0 mg
Number of subjects: 12
Study 2884081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29237800 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical care plus community-based programming
Number of subjects: 97
Study 29237800 — intervention group
Group type: COMPARATOR
Intervention: Clinical care
Number of subjects: 97
Study 26762743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and Pemetrexed (CPx)
Number of subjects: 132
Study 26762743 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and Vinorelbine (CVb)
Number of subjects: 132
Study 24947792 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU/week vitamin D3
Number of subjects: 511
Study 24947792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 22898163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (OSNAP)
Number of subjects: 20
Study 20543994 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent sexual and reproductive health intervention (teacher-led, peer-assisted education, youth-friendly health services, community activities, youth condom promotion and distribution)
Number of subjects: 13814
Study 18656765 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Number of subjects: 64
Study 18656765 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (lidocaine)
Number of subjects: 64
Study 16162255 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs (MA and MoA)
Number of subjects: 0
Study 16162255 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 11497140 — intervention group
Group type: EXPERIMENTAL
Intervention: Backflow technique (10 cm)
Number of subjects: 120
Study 11497140 — intervention group
Group type: EXPERIMENTAL
Intervention: Backflow technique (20 cm)
Number of subjects: 120
Study 11497140 — intervention group
Group type: EXPERIMENTAL
Intervention: Backflow technique (30 cm)
Number of subjects: 120
Study 11497140 — intervention group
Group type: COMPARATOR
Intervention: Conventional sampling
Number of subjects: 120
Study 11497140 — intervention group
Group type: EXPERIMENTAL
Intervention: Backflow technique
Number of subjects: 120
Study 9603138 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (600 mg)
Number of subjects: 10
Study 8310508 — intervention group
Group type: EXPERIMENTAL
Intervention: 33B3.1 (10 mg/day)
Number of subjects: 40
Study 8310508 — intervention group
Group type: COMPARATOR
Intervention: ATG (1 mg/kg/day)
Number of subjects: 40
Study 8310508 — intervention group
Group type: COMPARATOR
Intervention: ATG
Number of subjects: 40
Study 8310508 — intervention group
Group type: EXPERIMENTAL
Intervention: 33B3.1
Number of subjects: 40
Study 2449506 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vancomycin infused over 1 h
Number of subjects: 11
Study 2449506 — intervention group
Group type: COMPARATOR
Intervention: 500 mg vancomycin infused over 1 h
Number of subjects: 11
Study 31161343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar infarct with concurrent embolic infarcts
Number of subjects: 244
Study 31161343 — intervention group
Group type: COMPARATOR
Intervention: Lacunar infarct only
Number of subjects: 244
Study 29555621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Insulin Titration Intervention (MITI) program
Number of subjects: 113
Study 28919708 — intervention group
Group type: EXPERIMENTAL
Intervention: AOS group (AG, oral administration 10‐mg AOS daily)
Number of subjects: 248
Study 28919708 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, placebo daily)
Number of subjects: 248
Study 22988961 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES) in blacks
Number of subjects: 2597
Study 22988961 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES) in whites
Number of subjects: 2597
Study 22988961 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES) in Asians
Number of subjects: 2597
Study 22988961 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES) in all groups
Number of subjects: 2597
Study 22155903 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard gel
Number of subjects: 1723
Study 22155903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1723
Study 22155903 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard (compliant users)
Number of subjects: 1723
Study 19264879 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based Behavioral Family Systems Therapy (BFST)
Number of subjects: 18
Study 19264879 — intervention group
Group type: COMPARATOR
Intervention: Control group from previous study (n = 40)
Number of subjects: 18
Study 16504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0
Study 16504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 0
Study 16504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 0
Study 16504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine‐pyrimethamine (SP)
Number of subjects: 0
Study 16504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine‐sulphadoxine‐pyrimethamine (CQ‐SP)
Number of subjects: 0
Study 16504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine‐sulphadoxine‐pyrimethamine (AQ‐SP)
Number of subjects: 0
Study 16504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine‐sulphadoxine‐pyrimethamine (MQ‐SP)
Number of subjects: 0
Study 16504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate‐sulphadoxine‐pyrimethamine (AS‐SP)
Number of subjects: 0
Study 15585437 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 7.5 mg
Number of subjects: 88
Study 15585437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 11331959 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based technology for visual analysis and searchable storage of microarray image data
Number of subjects: 2
Study 11331959 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based technology for visual analysis
Number of subjects: 2
Study 9549739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal opioids (morphine and sufentanil) administered at L3-L4 after induction of anaesthesia
Number of subjects: 80
Study 9549739 — intervention group
Group type: COMPARATOR
Intervention: Control group (inhalation and intravenous narcotic anaesthesia)
Number of subjects: 80
Study 9549739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal opioids
Number of subjects: 80
Study 7890823 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic HIV‐1 infection
Number of subjects: 44
Study 7890823 — intervention group
Group type: COMPARATOR
Intervention: Seronegative (SN) controls
Number of subjects: 44
Study 3190999 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril hydrochloride
Number of subjects: 23
Study 3190999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31451438 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40
Study 31451438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31199342 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based happiness intervention with 1 of 14 possible 1-week activities (Sample 1)
Number of subjects: 2230
Study 31199342 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based happiness intervention with 0, 2, 4, or 6 weeks of activities (Sample 2)
Number of subjects: 2230
Study 28148632 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 42
Study 28148632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 26511911 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 30
Study 26511911 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study 23823086 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed Teen Triple P intervention (10-week program with 10 modules of 1 hour each)
Number of subjects: 79
Study 23823086 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 79
Study 21489749 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive modification of interpretation bias
Number of subjects: 103
Study 21489749 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative modification of interpretation bias
Number of subjects: 103
Study 21489749 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related effects
Number of subjects: 103
Study 21489749 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral task response
Number of subjects: 103
Study 21489749 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance behavior
Number of subjects: 103
Study 19882583 — intervention group
Group type: EXPERIMENTAL
Intervention: Xal-Ease
Number of subjects: 211
Study 19882583 — intervention group
Group type: COMPARATOR
Intervention: Dropper bottle
Number of subjects: 211
Study 22884136 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial pressure‐based cardiac output (APCO) monitoring
Number of subjects: 50
Study 22884136 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery catheter (PAC) monitoring
Number of subjects: 50
Study 22884136 — intervention group
Group type: EXPERIMENTAL
Intervention: APCO and PAC monitoring
Number of subjects: 50
Study 16422914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous sodium nitroprusside (SNP)
Number of subjects: 40
Study 16422914 — intervention group
Group type: COMPARATOR
Intervention: Papaverine/phentolamine (bimix)
Number of subjects: 40
Study 12853194 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 305
Study 12853194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 10215671 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methylnoradrenaline
Number of subjects: 6
Study 10215671 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 6
Study 10215671 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 6
Study 10215671 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 6
Study 8559866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 37
Study 8559866 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training
Number of subjects: 37
Study 8559866 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic Antidepressant Medication
Number of subjects: 37
Study 2713219 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol (1 g)
Number of subjects: 5
Study 2713219 — intervention group
Group type: COMPARATOR
Intervention: Oral chloramphenicol (500 mg)
Number of subjects: 5
Study 588391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 15
Study 588391 — intervention group
Group type: COMPARATOR
Intervention: Tubocurarine
Number of subjects: 15
Study 588391 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 15
Study 30418227 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 65
Study 30418227 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics without L-carnitine (control)
Number of subjects: 65
Study 30519904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to improve opioid prescribing practices in HIV outpatient clinics
Number of subjects: 0